SCAPE 张玉蛟教授 5/13/2015 在世界权威杂志柳叶刀 Lancet 发表重大临床科研成果,SABR 在手术可切除早期肺癌取得比手朮治疗更好的疗效。

MD 安德森肿瘤中心重大科研成果新闻, 今日国际柳叶刀肿瘤杂志发表,SABR 在手术可切除早期肺癌取得比手朮治疗更好的疗效。

枊叶刀杂志专设editorial. Stereotactic ablative radiotherapy achieves better overall survival than surgery for early lung cancer

Date:

May 13, 2015

Source:

University of Texas M. D. Anderson Cancer Center

Summary:

Patients with operable stage I non-small cell lung cancer (NSCLC) could achieve better overall survival rates if treated with Stereotactic Ablative Radiotherapy (SABR) rather than the current standard of care – invasive surgery – according to research from a phase III randomized international study.

FULL STORY

Patients with operable stage I non-small cell lung cancer (NSCLC) could achieve better overall survival rates if treated with Stereotactic Ablative Radiotherapy (SABR) rather than the current standard of care -- invasive surgery -- according to research from a phase III randomized international study from The University of Texas MD Anderson Cancer Center.

The findings, published today in The Lancet Oncology, are from the first randomized clinical trials comparing SABR and surgery.

"For the first time, we can say that the two therapies are at least equally effective, and that SABR appears to be better tolerated and might lead to better survival outcomes for these patients," said the first author and principal investigator Joe Y. Chang, M.D., Ph.D., professor, Radiation Oncology. "Stereotactic radiation treatment is a relatively new approach for operable early stage lung cancer, while surgery has been the standard for a century. This study can give physicians confidence to consider a non-invasive option."

Estimated three-year survival rates were 79 percent in the surgery group and 95 percent in the SABR group, while recurrence-free survival rates at three years were 80 percent and 86 perc

The authors suggest that the lower survival rate following surgery could be attributed to other simultaneous conditions that were worsened by the surgical reduction of lung function. As such, the findings support SABR as a non-invasive alternative, especially for elderly patients and for those with significant comorbidities.

"The findings of our study provide strong support for a large clinical trial to investigate the potential superiority of SABR for patients with early-stage disease," said senior author Jack A. Roth, M.D., Professor and Bud Johnson Clinical Distinguished Chair Department of Thoracic & Cardiovascular Surgery. "While we wait for more data, physicians can consider SABR an effective treatment for these patients, especially for those whom surgery brings high risk."

Journal Reference:

Joe Y Chang et al. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. The Lancet, 2015 DOI: 10.1016/S1470-2045(15)70168-3

University of Texas M. D. Anderson Cancer Center. "Stereotactic ablative radiotherapy achieves better overall survival than surgery for early lung cancer." ScienceDaily. ScienceDaily, 13 May 2015. <www.sciencedaily.com/releases/2015/05/150513210000.htm>.